Regarding the proactive recall of Omjjara Tablets 100 mg (batch number as stated in the text) by GSK plc., no such batch of drugs has been imported into Japan.

In myelofibrosis, hepcidin overexpression leads to anemia. Molotinib inhibits hepatic ALK2-mediated hepcidin expression, mobilizes intracellular iron into the bloodstream, stimulates erythropoiesis, and improves anemia.

Bevantolol (Carvan) is a prescription drug approved for marketing in Japan in June 1995; its primary targets include β1-adrenergic receptors, α1-adrenergic receptors, and L-type voltage-gated calcium channels, and it should be used in strict accordance with medical advice.

Gipritinib is a potent, selective, oral FMS-like tyrosine kinase 3 (FLT3) inhibitor. The approval of gipritinib was based on the global, multicenter, open-label, randomized, controlled phase III clinical trial ADMIRAL, which ultimately enrolled 371 patients with relapsed or refractory AML who had FLT3 mutations detected in their blood or bone marrow. These patients were randomized 2:1 to receive either gipritinib or salvage chemotherapy. The primary composite endpoint of the ADMIRAL study was overall survival (OS) and the rate of complete remission (CR/CRh) with complete or partial hematologic recovery. The results of this study were published in the prestigious medical journal *The New England Journal of Medicine* (NEJM).

Eltrombopag is a thrombopoietin receptor agonist that works by inducing the differentiation and proliferation of megakaryocytes (particularly large cells found in the bone marrow). It is indicated for the treatment of thrombocytopenia in patients with chronic immune thrombocytopenic purpura (ITP) who have not responded adequately to glucocorticoids, immunoglobulins, or splenectomy. Currently, eltrombopag is approved in more than 100 countries worldwide for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP), and in 43 countries for the treatment of thrombocytopenia in patients with chronic hepatitis C (CHC) to initiate and maintain standard interferon-based therapies for liver disease.

Eltrombopag is a thrombopoietin receptor agonist that works by inducing the differentiation and proliferation of megakaryocytes (particularly large cells found in the bone marrow). It is indicated for the treatment of thrombocytopenia in patients with chronic immune thrombocytopenic purpura (ITP) who have not responded adequately to glucocorticoids, immunoglobulins, or splenectomy. Currently, eltrombopag is approved in more than 100 countries worldwide for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP), and in 43 countries for the treatment of thrombocytopenia in patients with chronic hepatitis C (CHC) to initiate and maintain standard interferon-based therapies for liver disease.

Selinexor (ATG-010) was approved for marketing by the U.S. Food and Drug Administration (FDA) in 2019. Selinexor blocks the nuclear export of tumor suppressor, growth regulator, and anti-inflammatory proteins by binding to the nuclear export protein XPO1 (CRM1), promoting the accumulation of these proteins in the cell nucleus and enhancing their anti-cancer activity in cells.